Application of jungermanniaceae D in preparing anti-tumor medicaments and anti-tumor multi-drug resistance reversing medicaments

An anti-tumor drug, the technology of orcin D, which is applied in the direction of anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., can solve problems such as the application of orcin D that has not been seen

Inactive Publication Date: 2010-07-21
SHANDONG UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, among the many reports retrieved, there is no application of leaf orcin D in anti-tumor and tumor multi-drug resistance reversal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of jungermanniaceae D in preparing anti-tumor medicaments and anti-tumor multi-drug resistance reversing medicaments
  • Application of jungermanniaceae D in preparing anti-tumor medicaments and anti-tumor multi-drug resistance reversing medicaments
  • Application of jungermanniaceae D in preparing anti-tumor medicaments and anti-tumor multi-drug resistance reversing medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Determination of the activity of orcin D to DNA topoisomerase I (TopoI) and topoisomerase II (TopoII)

[0020] (1) Formation of Leptosperin D:

[0021] Use an analytical balance to take 5 mg of phylloxin D, add 1179.24 μl of DMSO (cell culture grade) to obtain a 10 mM stock solution, and store it at -20°C (dilute to the required concentration with the medium before use).

[0022] (2) Extraction of DNA topoisomerase:

[0023] Collect K562 cells about 1×10 8 , wash twice with 4°C pre-cooled PBS, add lysate (20mM Tris, 1mM EGTA, 25mM KCI, 5mM MgCl 2 , 250mM sucrose, 0.5% NP40, pH 7.2) 1ml, lyse at 4°C for 10min, centrifuge at 6000rpm for 2min, add 50μl nuclear extract (20mM Tris, 1mM EGTA, 2mM EDTA, 2mM DTT, 400mM NaCl, pH 7.2) to the pellet and pipette evenly, Incubate on ice for 30 minutes, centrifuge at 14,000 rpm for 15 minutes, carefully aspirate the supernatant, measure the protein content with the Coomassie Brilliant Blue method, and store at -20°C aft...

Embodiment 2

[0031] Example 2: Real-time Quantitative PCR Detection of the Inhibitory Effect of Leaforcin D on DNA Topoisomerase IIα Subtype (TopoIIα)

[0032] (1) RNA extraction

[0033] a. Cell treatment: Take K562 cells in the exponential growth phase and inoculate them in 6-well plates, the number of cells is 2×10 5 each / well, and at the same time, add different concentrations of leafletin D, and the final concentrations are 10, 20, and 30 μM, respectively. Set at 37°C, 5% CO 2 After culturing in the incubator for 24 hours, the cells were collected into 1.5ml Ep tubes, washed twice with PBS, 3000rpm×5min.

[0034]b. Extraction of total RNA: Take the above precipitate and add 0.5ml Trizol to mix well, then add 100μl chloroform, mix up and down several times, room temperature for 5min. Centrifuge at 4°C, 12000G×15min. Then carefully pipette the upper aqueous phase containing total RNA into a new DEPC-treated Ep tube, and do not inhale any substance in the middle layer. 1ml Trizol ca...

Embodiment 3

[0054] Example 3: The growth inhibitory effect of lamellarin D on K562 / A02 cells

[0055] Method: MTT method: take chronic myelogenous leukemia drug-resistant cell line K562 / A02, 2×10 4 Cells per well were seeded in a 96-well plate, and 0.4% DMSO and different concentrations of orcin D were added respectively. After culturing for 24, 48 and 72 hours, 20 μl of 5 mg / ml MTT was added to each well and continued to incubate for 4 hours. 200 μl of DMSO was shaken slightly to completely dissolve the formed formazan for color development, and the OD value was measured at a wavelength of 570 nm with a Bio-Rad Model 550 Microplate Reader. The experiment was carried out three times under different culture time conditions, and the average value was calculated.

[0056] Result: if Figure 4 As shown, it can be seen from the figure that the 24, 48 and 72 h cultured under the condition of 2 to 10 μg / ml, respectively, has no obvious inhibitory effect on the K562 / A02 cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention discloses a new use of jungermanniaceae D, namely the application of the jungermanniaceae D in preparing anti-tumor medicaments and anti-tumor multi-drug resistance reversing medicaments. Research results show that the jungermanniaceae D can inhibit the expression of a gene alpha subtype of topoisomerase II, can selectively inhibit the activity of the topoisomerase II and has an obvious anti-tumor action, and simultaneously the compound can inhibit P-glycoprotein and shows good tumor multi-drug resistance reversing activity, so the jungermanniaceae D is a chemotherapy medicament which specially has a development prospect, and can serve as a main component for preparing anti-tumor oral preparations and injections, multi-drug resistance reversing oral preparations and injections and the like.

Description

technical field [0001] The present invention relates to a new application of leaf orcin D, in particular to its application in the preparation of anti-tumor drugs and anti-tumor multi-drug resistance reversal drugs. Background technique [0002] Tumor is a kind of disease that seriously endangers human health and quality of life. The discovery and development of anti-tumor drugs has always been the focus and hot spot of drug researchers. At present, there are a large number of people suffering from cancer in our country, and more than 1.6 million people die from cancer every year. In the past two decades, the cancer mortality rate in my country has increased by 29.42%. Among the middle-aged and middle-aged people aged 35 to 59, tumor ranks first among various causes of death, and has become an important cause of the loss of the best labor force in our country. Therefore, the development and development of new anti-tumor drugs is a work of great significance. [0003] Ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/335A61P35/00
Inventor 娄红祥孙斌薛霞沈涛李霞范培红
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap